Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-CIDEB · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ALN-CIDEB Dose 1 | EXPERIMENTAL | - |
| ALN-CIDEB Dose 2 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Part A | EXPERIMENTAL | Randomized per the protocol |
| Part B | EXPERIMENTAL | Randomized per the protocol |
| Name | Type | Description |
|---|---|---|
| ALN-CIDEB | DRUG | Administered per the protocol |
| Placebo | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers and clinical risk factors, including having a history of 1 or more elements of metabolic syndrome as described in the protocol 2. Screenin...
ALN-CIDEB is an investigational drug being developed for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It is being studied in adult participants with these liver conditions, including those with fibrotic MASH.
ALN-CIDEB is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol REGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metabolic liver diseases.
ALN-CIDEB is currently in Phase 2 clinical development. It is being evaluated in a Phase 2 study for fibrotic MASH, and it is also being studied in an earlier-phase trial for MASLD and MASH. The drug is investigational and not yet approved by regulatory authorities.
ALN-CIDEB is being studied in two clinical trials. NCT06836609 is a Phase 1 study in adults with MASLD or MASH, enrolling 132 participants in the United States and United Kingdom. NCT07631637 is a Phase 2 study in adults with fibrotic MASH, enrolling 150 participants.
ALN-CIDEB is the primary name used for this investigational drug in clinical trials. No alternative names have been reported for this compound. It is being developed specifically for metabolic liver diseases and is not known to be marketed under any other brand name.